NEW YORK (TheStreet) -- Teva Pharmaceuticals (TEVA) - Get Teva Pharmaceutical Industries Limited Sponsored ADR Report is expected to post fiscal 2016 second-quarter results before Thursday's opening bell.
Analysts project that the Israeli pharmaceuticals company will report earnings of $1.20 per share on revenue of $4.87 billion. The company itself expects to see revenues between $4.7 billion and $4.9 billion for the second quarter.
Teva posted earnings of $1.43 per share on revenue of $4.97 billion for the 2015 second quarter.
Last week, the company announced it is purchasing Allergan's (AGN) generics business, Anda, for $500 million. Teva will also acquire three U.S. distribution centers with a total of 650 employees as part of the deal.
Shares of Teva were rising in late-afternoon trading on Wednesday.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate TEVA PHARMACEUTICALS as a Buy with a ratings score of B. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: TEVA